Dr. Montagna is a senior scientist at the Immunology and Molecular Oncology Unit of the Veneto Institute of Oncology. Since 1990 his major research projects focused on the genetic basis of cancer. The first studies aimed at the understanding of genomic imprinting dysregulation and identification of new loci involved in the pathogenesis of hepatoblastoma. The study of the genetic factors predisposing to breast and ovarian cancer started in 1995 at the International Agency for Research on Cancer in Lyon and became the major scientific interest over the last 25 years. In 2005 he joined the CIMBA international consortium whose main goal is to perform large-scale genomic studies in order to identify genetic modifiers of the risk associated to BRCA1/2 mutations. Few years later he became a member of the ENIGMA consortium with a focus on the investigation of the clinical relevance of BRCA1 and BRCA2 sequence variants of uncertain significance. Since 1994 he published 119 scientific papers on peer-reviewed journals. As team leader of the IOV Hereditary Breast and Ovarian Cancer Unit, Dr. Montagna recently spent much of his efforts in translating the most recent research scientific achievements on breast and ovarian cancer predisposition into clinical-diagnostic pathways dedicated to risk assessment and genetic testing for cancer prevention/early detection and targeted therapy.
Hereditary Breast and Ovarian Cancer Unit
– Immunology and Molecular Oncology Unit
– Department of Translational Oncology and Health Services, IOV-IRCCS
- phone: ++39 049 821 5881
- fax: ++39 049 821 5967
- ORCID: 0000-0002-4929-2150